Raf Kinase inhibitor protein expression in a survival analysis of colorectal cancer patients

F. Al-Mulla, S. Hagan, A. I. Behbehani, M. S. Bitar, S. S. George, J. J. Going, J. J. Curto Garcia, L. Scott, N. Fyfe, Graeme Ian Murray, W. Kolch

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

Purpose Raf kinase inhibitor protein (RKIP) inhibits the Raf and nuclear factor kappa B signaling pathways, and suppresses metastasis in animal models. We examined whether RKIP expression in primary colorectal cancers (CRCs) correlates with the risk of metastasis and overall survival.

Patients and Methods RKIP expression was examined immunohistochemically in three separate cohorts: a tissue microarray containing 276 samples from human tumors and normal tissues, and retrospective studies of 268 CRC patients and 65 early-stage CRCs. Overall and metastasis-free survival rates were measured.

Results RKIP was expressed in normal epithelia but was reduced in metastatic tumors. RKIP expression in primary CRC was an independent prognostic marker for survival using multivariate Cox regression analysis (hazard ratio, 2.808; 95% CI, 1.58 to 4.96; P = .0002), independent of Dukes' stage. Patients with Dukes' C RKIP-positive tumors had similar 5-year survival rates as early-stage patients if tumors had equivalent RKIP expression levels. An independent study of early-stage CRCs confirmed that reduced RKIP expression predicted metastatic recurrence and reduced disease-free survival (hazard ratio, 4.5; 95% CI, 1.7 to 12.3; P = .003). RKIP expression was independent of sex, age, mitotic index, lymphatic and vascular invasion, depth of invasion, and tumor site, but correlated positively with apoptotic index (P = .024). Weak or loss of RKIP expression was the most significant and independent prognostic marker using a multivariate regression equation (hazard ratio, 4.5; 95% CI, 1.7 to 12.3; P = .003).

Conclusion RKIP expression in primary CRCs correlates with overall and disease-free survival, and can be useful for identifying early-stage CRC patients at risk of relapse.

Original languageEnglish
Pages (from-to)5672-5679
Number of pages7
JournalJournal of Clinical Oncology
Volume24
DOIs
Publication statusPublished - 2006

Keywords

  • COLON-CANCER
  • DUKES-B
  • TISSUE MICROARRAY
  • PROSTATE-CANCER
  • MAP KINASE
  • METASTASIS
  • PROGNOSIS
  • RKIP
  • SUPPRESSION
  • MARKERS

Cite this

Al-Mulla, F., Hagan, S., Behbehani, A. I., Bitar, M. S., George, S. S., Going, J. J., ... Kolch, W. (2006). Raf Kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. Journal of Clinical Oncology, 24, 5672-5679. https://doi.org/10.1200/JCO.2006.07.5499

Raf Kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. / Al-Mulla, F.; Hagan, S.; Behbehani, A. I.; Bitar, M. S.; George, S. S.; Going, J. J.; Curto Garcia, J. J.; Scott, L.; Fyfe, N.; Murray, Graeme Ian; Kolch, W.

In: Journal of Clinical Oncology, Vol. 24, 2006, p. 5672-5679.

Research output: Contribution to journalArticle

Al-Mulla, F, Hagan, S, Behbehani, AI, Bitar, MS, George, SS, Going, JJ, Curto Garcia, JJ, Scott, L, Fyfe, N, Murray, GI & Kolch, W 2006, 'Raf Kinase inhibitor protein expression in a survival analysis of colorectal cancer patients', Journal of Clinical Oncology, vol. 24, pp. 5672-5679. https://doi.org/10.1200/JCO.2006.07.5499
Al-Mulla, F. ; Hagan, S. ; Behbehani, A. I. ; Bitar, M. S. ; George, S. S. ; Going, J. J. ; Curto Garcia, J. J. ; Scott, L. ; Fyfe, N. ; Murray, Graeme Ian ; Kolch, W. / Raf Kinase inhibitor protein expression in a survival analysis of colorectal cancer patients. In: Journal of Clinical Oncology. 2006 ; Vol. 24. pp. 5672-5679.
@article{be36e14a3afe4b62975258fca0978ea7,
title = "Raf Kinase inhibitor protein expression in a survival analysis of colorectal cancer patients",
abstract = "Purpose Raf kinase inhibitor protein (RKIP) inhibits the Raf and nuclear factor kappa B signaling pathways, and suppresses metastasis in animal models. We examined whether RKIP expression in primary colorectal cancers (CRCs) correlates with the risk of metastasis and overall survival.Patients and Methods RKIP expression was examined immunohistochemically in three separate cohorts: a tissue microarray containing 276 samples from human tumors and normal tissues, and retrospective studies of 268 CRC patients and 65 early-stage CRCs. Overall and metastasis-free survival rates were measured.Results RKIP was expressed in normal epithelia but was reduced in metastatic tumors. RKIP expression in primary CRC was an independent prognostic marker for survival using multivariate Cox regression analysis (hazard ratio, 2.808; 95{\%} CI, 1.58 to 4.96; P = .0002), independent of Dukes' stage. Patients with Dukes' C RKIP-positive tumors had similar 5-year survival rates as early-stage patients if tumors had equivalent RKIP expression levels. An independent study of early-stage CRCs confirmed that reduced RKIP expression predicted metastatic recurrence and reduced disease-free survival (hazard ratio, 4.5; 95{\%} CI, 1.7 to 12.3; P = .003). RKIP expression was independent of sex, age, mitotic index, lymphatic and vascular invasion, depth of invasion, and tumor site, but correlated positively with apoptotic index (P = .024). Weak or loss of RKIP expression was the most significant and independent prognostic marker using a multivariate regression equation (hazard ratio, 4.5; 95{\%} CI, 1.7 to 12.3; P = .003).Conclusion RKIP expression in primary CRCs correlates with overall and disease-free survival, and can be useful for identifying early-stage CRC patients at risk of relapse.",
keywords = "COLON-CANCER, DUKES-B, TISSUE MICROARRAY, PROSTATE-CANCER, MAP KINASE, METASTASIS, PROGNOSIS, RKIP, SUPPRESSION, MARKERS",
author = "F. Al-Mulla and S. Hagan and Behbehani, {A. I.} and Bitar, {M. S.} and George, {S. S.} and Going, {J. J.} and {Curto Garcia}, {J. J.} and L. Scott and N. Fyfe and Murray, {Graeme Ian} and W. Kolch",
year = "2006",
doi = "10.1200/JCO.2006.07.5499",
language = "English",
volume = "24",
pages = "5672--5679",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",

}

TY - JOUR

T1 - Raf Kinase inhibitor protein expression in a survival analysis of colorectal cancer patients

AU - Al-Mulla, F.

AU - Hagan, S.

AU - Behbehani, A. I.

AU - Bitar, M. S.

AU - George, S. S.

AU - Going, J. J.

AU - Curto Garcia, J. J.

AU - Scott, L.

AU - Fyfe, N.

AU - Murray, Graeme Ian

AU - Kolch, W.

PY - 2006

Y1 - 2006

N2 - Purpose Raf kinase inhibitor protein (RKIP) inhibits the Raf and nuclear factor kappa B signaling pathways, and suppresses metastasis in animal models. We examined whether RKIP expression in primary colorectal cancers (CRCs) correlates with the risk of metastasis and overall survival.Patients and Methods RKIP expression was examined immunohistochemically in three separate cohorts: a tissue microarray containing 276 samples from human tumors and normal tissues, and retrospective studies of 268 CRC patients and 65 early-stage CRCs. Overall and metastasis-free survival rates were measured.Results RKIP was expressed in normal epithelia but was reduced in metastatic tumors. RKIP expression in primary CRC was an independent prognostic marker for survival using multivariate Cox regression analysis (hazard ratio, 2.808; 95% CI, 1.58 to 4.96; P = .0002), independent of Dukes' stage. Patients with Dukes' C RKIP-positive tumors had similar 5-year survival rates as early-stage patients if tumors had equivalent RKIP expression levels. An independent study of early-stage CRCs confirmed that reduced RKIP expression predicted metastatic recurrence and reduced disease-free survival (hazard ratio, 4.5; 95% CI, 1.7 to 12.3; P = .003). RKIP expression was independent of sex, age, mitotic index, lymphatic and vascular invasion, depth of invasion, and tumor site, but correlated positively with apoptotic index (P = .024). Weak or loss of RKIP expression was the most significant and independent prognostic marker using a multivariate regression equation (hazard ratio, 4.5; 95% CI, 1.7 to 12.3; P = .003).Conclusion RKIP expression in primary CRCs correlates with overall and disease-free survival, and can be useful for identifying early-stage CRC patients at risk of relapse.

AB - Purpose Raf kinase inhibitor protein (RKIP) inhibits the Raf and nuclear factor kappa B signaling pathways, and suppresses metastasis in animal models. We examined whether RKIP expression in primary colorectal cancers (CRCs) correlates with the risk of metastasis and overall survival.Patients and Methods RKIP expression was examined immunohistochemically in three separate cohorts: a tissue microarray containing 276 samples from human tumors and normal tissues, and retrospective studies of 268 CRC patients and 65 early-stage CRCs. Overall and metastasis-free survival rates were measured.Results RKIP was expressed in normal epithelia but was reduced in metastatic tumors. RKIP expression in primary CRC was an independent prognostic marker for survival using multivariate Cox regression analysis (hazard ratio, 2.808; 95% CI, 1.58 to 4.96; P = .0002), independent of Dukes' stage. Patients with Dukes' C RKIP-positive tumors had similar 5-year survival rates as early-stage patients if tumors had equivalent RKIP expression levels. An independent study of early-stage CRCs confirmed that reduced RKIP expression predicted metastatic recurrence and reduced disease-free survival (hazard ratio, 4.5; 95% CI, 1.7 to 12.3; P = .003). RKIP expression was independent of sex, age, mitotic index, lymphatic and vascular invasion, depth of invasion, and tumor site, but correlated positively with apoptotic index (P = .024). Weak or loss of RKIP expression was the most significant and independent prognostic marker using a multivariate regression equation (hazard ratio, 4.5; 95% CI, 1.7 to 12.3; P = .003).Conclusion RKIP expression in primary CRCs correlates with overall and disease-free survival, and can be useful for identifying early-stage CRC patients at risk of relapse.

KW - COLON-CANCER

KW - DUKES-B

KW - TISSUE MICROARRAY

KW - PROSTATE-CANCER

KW - MAP KINASE

KW - METASTASIS

KW - PROGNOSIS

KW - RKIP

KW - SUPPRESSION

KW - MARKERS

U2 - 10.1200/JCO.2006.07.5499

DO - 10.1200/JCO.2006.07.5499

M3 - Article

VL - 24

SP - 5672

EP - 5679

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

ER -